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Impact on adherence of a telephone follow up strategy in HIV-
naı ¨ve patients who start antiretroviral therapy: cohort study
Bullo, M; Toibaro, J and Losso, M
Hospital Ramos Mejı ´a, Inmunocomprometidos, Buenos Aires, Argentina.
Antiretroviral therapy changed the prognosis of people living with HIV/AIDS. However, lack of adherence jeopardizes the success
of antiretroviral therapy and enhances the development of treatment-resistant strains, treatment failure, and therefore it stands
as a public health problem. The main goal of this study was to measure the impact on treatment discontinuations and lost to
follow up, of a telephone follow-up strategy in naı ¨ve patients who start antiretroviral therapy.We conducted a single-site, cohort
study during a 12-month period (May 2011May 2012). A prospective cohort of naı ¨ve patients received the standard of care
plus a specific telephone follow-up strategy. Results were compared with a retrospective cohort of naı ¨ve patients followed up at
the same site, who started antiretroviral therapy receiving only the standard of care during a similar period (JanuaryDecember
2009). We used descriptive statistics and Fisher exact test for the comparisons of variables. We enrolled 41 patients in the
prospective cohort and 50 in the retrospective one. Both cohorts had similar general characteristics. We found a lower number
of patients who were lost to follow up in the prospective cohort (intervention) consistent with lower rates of treatment
abandonment, suspensions and a similar tendency for events, including death, even when none of these findings was
statistically significant. Baseline characteristics and main results are shown in the table below. Further randomized studies
should be conducted applying a telephone follow-up strategy to confirm these findings.
Non intervention group (n: 50) Intervention Group (n: 41) p
Age (mean in years) 36 35 0.58
Women n (%) 17 (34%) 23 (56%) 0.034
Heterosexual n (%) 33 (66%) 28 (68%) 0.81
Education, years (mean) 10.02 10.39 0.58
Preexistent serious disease 6 (12%) 5 (12%) 1
Previous opportunistic events (%) 16 (32%) 10 (24%) 0.28
Baseline CD4 count, median (range) 176 (7783) 222 (20868) 0.12
Baseline HIV RNA, log 4.89 4.22 0.001
Abandonment of treatment 9 (18%) 3 (7%) 0.021
Change of treatment 10 (20%) 14 (34%) 0.042
Lost to follow up 23 (46%) 10 (24%) 0.032
Hospitalization after HAART 4 (8%) 3 (7%) 0.3
New opportunistic event 3 (6%) 0 (0%) N/A
Death 2 (4%) 1 (2.4%) 0.41
CD4/mm
3 at 24 weeks (median) 315 384 0.151
Log HIV RNA at 24 weeks (median) 1.69 1.69
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